ImpediMed, a leader in medical technologies for clinically monitoring and managing fluid and body composition, announced an agreement for a five-year $15 million growth capital facility with SWK Holdings, a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies. The funds raised will give ImpediMed funding flexibility and will be used to support growth and commercialization activities.
With this new funding round, ImpediMed’s capital base is well-equipped to support the continued execution of its commercial strategy. So the company is better positioned than ever to achieve its long-term goals and create significant value for its shareholders.
As a pioneer in the field of lymphedema detection and monitoring, ImpediMed provides the only FDA-cleared bioimpedance spectroscopy (BIS) technology for the clinical assessment of breast cancer-related lymphedema (BCRL), the SOZO Digital Health Platform. And ImpediMed’s platform is broadly accepted and recognized for effective and accurate screening of lymphedema, with U.S. health payors now providing coverage for over 258 million covered lives.
Lymphedema—a common consequence of cancer treatment—is challenging to detect before symptoms appear. ImpediMed’s SOZO Digital Health Platform uses BIS to identify fluid changes early, enabling intervention before lymphedema becomes a chronic condition. With growing adoption in clinical practice and increasing payor coverage, ImpediMed’s innovative approach is transforming lymphedema management.
Last year, the National Accreditation Program for Breast Centers (NABPC) updated its accreditation standards to include lymphedema prevention programs utilizing BIS as an evidence-based guideline for managing lymphedema. And the NAPBC is a quality program of the American College of Surgeons, and accredited programs must understand, implement, and demonstrate compliance with accreditation standards outlined in Optimal Resources for Breast Care.
This recognition also further validates BIS as a critical tool in lymphedema management and presents a significant opportunity for ImpediMed to expand its reach, driving broader adoption of the SOZO Digital Health Platform across breast cancer centers nationwide.
Armentum Partners acted as the Company’s exclusive financial advisor on this transaction.
KEY QUOTES:
“We are pleased with our agreement with SWK Holdings and the confidence they have shown in ImpediMed, as well as in the future of our SOZO Digital Health Platform. SWK’s proven approach of supporting innovative healthcare companies makes them an ideal partner for us as we pursue our commercial growth strategy over the next five years. We are confident with the business’ direction, and this was reinforced throughout our due diligence process. In conjunction with our existing cash reserves, this facility gives us the time and funding flexibility required to execute on our business plan and fully capitalize on the BCRL opportunity.”
- Dr. Parmjot Bains, MD, CEO & Managing Director of ImpediMed
“We believe that the SOZO Digital Health Platform is revolutionizing how clinicians assess and manage fluid and body composition, ultimately improving patient outcomes. We are excited to provide this capital to support ImpediMed’s continued mission to improve the lives of patients by pushing the boundaries of what’s possible in fluid and tissue analysis.”
• ⁃ JD Tamas, Director of Underwriting at SWK Holdings
